drug_type
RELEVANT_DRUG
intervention_type
Cellular gene immunotherapy (CAR T-cell therapy)
drug_description
Autologous, retroviral-transduced anti-BCMA (TNFRSF17) chimeric antigen receptor T-cell therapy that targets BCMA-expressing B-lineage cells (plasmablasts and long-lived plasma cells) to deplete autoantibody-producing cells in refractory B cell–mediated autoimmune diseases; administered as a single IV infusion following lymphodepletion.
nci_thesaurus_concept_id
C205068
nci_thesaurus_preferred_term
Autologous Anti-BCMA-CAR-4-1BB-expressing T-cells NXC-201
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA-CAR-4-1BB-expressing T-cells NXC-201 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA, found on the surfaces of plasma cells and overexpressed on malignant plasma cells, plays a key role in plasma cell survival.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are retrovirally transduced to express an anti-BCMA chimeric antigen receptor with a 4-1BB costimulatory domain; upon infusion, these CAR-T cells recognize BCMA (TNFRSF17) on plasmablasts and long-lived plasma cells and mediate cytotoxic killing, depleting BCMA-positive B-lineage cells and reducing autoantibody production.
drug_name
HBI0101
nct_id_drug_ref
NCT07085676